A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC 704865 IND 7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer.
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Feb 2012 Health-related quality-of-life substudy results published in the Journal of Pain and Symptom Management.
- 02 Mar 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History